Skip to content
Triangle logo TriangleGet started
← AIDS-Related Lymphoma

NCT05510908 · STUDY IN CONTEXT

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

exploratory · POSTED

The distribution of participant cancer diagnosis variable will be summarized.

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant gender variable will be summarized.

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).

Participants who enrolled in this study

→

exploratory · POSTED

The distribution of participant cancer treatment at enrollment will be summarized.

Participants who enrolled in this study

→

primary · POSTED

For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies

Source null

→

secondary · POSTED

This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

The participants who are eligible to meet site-based AMC trial eligibility

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

EORTC QLQ · Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-aids-related-lymphoma
nct id
NCT05510908
qol key
qol-0007
source section id
NCT05510908-om-0007
source outcome index
7
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition
EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame
Baseline
analysis role
exploratory
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Participants who enrolled in this study with EORTC QLQ-C30 information
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
EORTC QLQ · Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-aids-related-lymphoma
nct id
NCT05510908
qol key
qol-0009
source section id
NCT05510908-om-0009
source outcome index
9
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
measure definition
EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
time frame
Baseline and 12 weeks
analysis role
exploratory
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Participants who enrolled with EORTC QLQ-C30 measurements for baseline and 12 weeks
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-aids-related-lymphoma
nct id
NCT05510908
trial label
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
3
qol Count
2
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0002
    source section id
    NCT05510908-om-0002
    source outcome index
    2
    endpoint
    Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
    endpoint definition
    The distribution of participant cancer diagnosis variable will be summarized.
    time origin
    Baseline
    analysis role
    exploratory
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Participants who enrolled in this study
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0003
    source section id
    NCT05510908-om-0003
    source outcome index
    3
    endpoint
    Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
    endpoint definition
    The distribution of participant gender variable will be summarized.
    time origin
    Baseline
    analysis role
    exploratory
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Participants who enrolled in this study
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0004
    source section id
    NCT05510908-om-0004
    source outcome index
    4
    endpoint
    Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
    endpoint definition
    The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).
    time origin
    Baseline and 12 weeks
    analysis role
    exploratory
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Participants who enrolled in this study
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0005
    source section id
    NCT05510908-om-0005
    source outcome index
    5
    endpoint
    Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
    endpoint definition
    The distribution of participant cancer treatment at enrollment will be summarized.
    time origin
    Baseline
    analysis role
    exploratory
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Participants who enrolled in this study
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0000
    source section id
    NCT05510908-om-0000
    source outcome index
    0
    endpoint
    Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites
    endpoint definition
    For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies
    time origin
    Enrollment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0001
    source section id
    NCT05510908-om-0001
    source outcome index
    1
    endpoint
    Proportion of Participants Eligible for AMC Trials Who Are Successfully Enrolled
    endpoint definition
    This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.
    time origin
    Baseline
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    The participants who are eligible to meet site-based AMC trial eligibility
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0000
    arm key
    OG000
    arm label
    New, Primary or Recurrent Disease
    regimen
    Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    268
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Metastic or Locally Advanced Cancer
    regimen
    This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    33
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0000
    arm key
    OG002
    arm label
    Prior Cancer
    regimen
    Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
    analyzed count
    159
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0000#groups/OG002
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0001
    arm key
    OG000
    arm label
    New, Primary or Recurrent Disease
    regimen
    Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    20
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0001#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Metastic or Locally Advanced Cancer
    regimen
    This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    2
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0001#groups/OG001
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0001
    arm key
    OG002
    arm label
    Prior Cancer
    regimen
    Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
    analyzed count
    4
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0001#groups/OG002
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0002
    arm key
    OG000
    arm label
    New, Primary or Recurrent Disease
    regimen
    Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    268
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0002#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Metastic or Locally Advanced Cancer
    regimen
    This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    33
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0002#groups/OG001
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0002
    arm key
    OG002
    arm label
    Prior Cancer
    regimen
    Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
    analyzed count
    159
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0002#groups/OG002
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0003
    arm key
    OG000
    arm label
    New, Primary or Recurrent Disease
    regimen
    Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    268
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0003#groups/OG000
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0003
    arm key
    OG001
    arm label
    Metastic or Locally Advanced Cancer
    regimen
    This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
    analyzed count
    33
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0003#groups/OG001
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    outcome key
    om-0003
    arm key
    OG002
    arm label
    Prior Cancer
    regimen
    Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
    analyzed count
    159
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05510908-om-0003#groups/OG002
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    harm key
    EG000
    source section id
    NCT05510908-ae
    event group key
    EG000
    event group label
    New, Primary or Recurrent Disease
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    This study is observational study. Adverse events are not collected.
    event definition
    This study is observational study. Adverse events are not collected.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    harm key
    EG001
    source section id
    NCT05510908-ae
    event group key
    EG001
    event group label
    Metastic or Locally Advanced Cancer
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    This study is observational study. Adverse events are not collected.
    event definition
    This study is observational study. Adverse events are not collected.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    harm key
    EG002
    source section id
    NCT05510908-ae
    event group key
    EG002
    event group label
    Prior Cancer
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    This study is observational study. Adverse events are not collected.
    event definition
    This study is observational study. Adverse events are not collected.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    qol key
    qol-0007
    source section id
    NCT05510908-om-0007
    source outcome index
    7
    instrument
    EORTC QLQ
    instrument basis
    matched 'eortc' in the study's own wording
    scale title
    Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
    measure definition
    EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
    time frame
    Baseline
    analysis role
    exploratory
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Participants who enrolled in this study with EORTC QLQ-C30 information
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-aids-related-lymphoma
    nct id
    NCT05510908
    qol key
    qol-0009
    source section id
    NCT05510908-om-0009
    source outcome index
    9
    instrument
    EORTC QLQ
    instrument basis
    matched 'eortc' in the study's own wording
    scale title
    Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
    measure definition
    EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
    time frame
    Baseline and 12 weeks
    analysis role
    exploratory
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Participants who enrolled with EORTC QLQ-C30 measurements for baseline and 12 weeks
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
setting source links

    Preserved source evidence · Not medical advice